{"id":620334,"date":"2022-10-10T17:26:02","date_gmt":"2022-10-10T17:26:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=620334"},"modified":"2022-10-10T17:26:02","modified_gmt":"2022-10-10T17:26:02","slug":"hereditary-transthyretin-amyloidosis-hattr-market-is-expected-to-showcase-a-significant-growth-by-2032-predicts-delveinsight-alnylam-akcea-ionis-astrazeneca-eidos-corino-prothena","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hereditary-transthyretin-amyloidosis-hattr-market-is-expected-to-showcase-a-significant-growth-by-2032-predicts-delveinsight-alnylam-akcea-ionis-astrazeneca-eidos-corino-prothena_620334.html","title":{"rendered":"Hereditary Transthyretin Amyloidosis (hATTR) Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Alnylam, Akcea, Ionis, AstraZeneca, Eidos, Corino, Prothena"},"content":{"rendered":"
\n
\"Hereditary<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Hereditary Transthyretin Amyloidosis (hATTR) Market market size in the seven major markets was found to be USD 973.5 million in 2020, which is expected to grow by 2032. The United States accounts for the largest market size of hATTR compared to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. In the United States, the market size of hATTR was found to be USD 529.6 million in 2020.<\/div>\n

The hATTR market<\/strong> is expected to grow owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.<\/em><\/p>\n

DelveInsight’s “Hereditary Transthyretin Amyloidosis (hATTR) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hereditary Transthyretin Amyloidosis (hATTR) Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Hereditary Transthyretin Amyloidosis (hATTR) market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Hereditary<\/p>\n

Hereditary Transthyretin Amyloidosis (hATTR): An Overview<\/strong><\/p>\n

Hereditary transthyretin amyloidosis (hATTR), an inherited, rapidly progressive, and life-threatening disease, is caused by a mutation in the transthyretin (TTR) gene that results in misfolded TTR proteins accumulating as amyloid fibrils in multiple sites, including the nerves, heart, and gastrointestinal tract. TTR protein is produced primarily in the liver and is usually a carrier for retinol-binding protein—one of the media used to transport vitamin A around the body.<\/p>\n

hATTR amyloidosis involves many systems in the body and can result in a wide variety of symptoms, including sensory and motor, autonomic (e.g., diarrhea, hypotension, erectile dysfunction), and cardiac symptoms.<\/em><\/p>\n

Hereditary Transthyretin Amyloidosis (hATTR) Market Key Facts<\/strong><\/p>\n